TY - JOUR AU - Milicic, A AU - Rollier, CS AU - Tang, CK AU - Longley, R AU - Hill, AVS AU - Reyes-Sandoval, A Y2 - 2020/12/10 Y1 - 2017/08/04 SN - 2045-2322 UR - http://hdl.handle.net/11343/253528 AB - The majority of routinely given vaccines require two or three immunisations for full protective efficacy. Single dose vaccination has long been considered a key solution to improving the global immunisation coverage. Recent infectious disease outbreaks have further highlighted the need for vaccines that can achieve full efficacy after a single administration. Viral vectors are a potent immunisation platform, benefiting from intrinsic immuno-stimulatory features while retaining excellent safety profile through the use of non-replicating viruses. We investigated the scope for enhancing the protective efficacy of a single dose adenovirus-vectored malaria vaccine in a mouse model of malaria by co-administering it with vaccine adjuvants. Out of 11 adjuvants, only two, Abisco®-100 and CoVaccineHTTM, enhanced vaccine efficacy and sterile protection following malaria challenge. The CoVaccineHTTM adjuvanted vaccine induced significantly higher proportion of antigen specific central memory CD8+ cells, and both adjuvants resulted in increased proportion of CD8+ T cells expressing the CD107a degranulation marker in the absence of IFNγ, TNFα and IL2 production. Our results show that the efficacy of vaccines designed to induce protective T cell responses can be positively modulated with chemical adjuvants and open the possibility of achieving full protection with a single dose immunisation. LA - English PB - NATURE PUBLISHING GROUP T1 - Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria DO - 10.1038/s41598-017-07246-0 IS - Scientific Reports VL - 7 IS - 1 L1 - /bitstream/handle/11343/253528/PMC5544665.pdf?sequence=1&isAllowed=y ER -